Amy Rommel

Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC

Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone

Molecular mechanisms and physiological importance of circadian rhythms

Inflammation and Cancer: Triggers, Mechanisms, and Consequences

R loops: new modulators of genome dynamics and function

The multidimensional mechanisms of long noncoding RNA function

The obese adipose tissue microenvironment in cancer development and progression

From Krebs to clinic: glutamine metabolism to cancer therapy

Reactive oxygen species (ROS) as pleiotropic physiological signalling agents

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth

Oxidative Stress in Cancer

Cisplatin: The first metal based anticancer drug

Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma

VEGF in Signaling and Disease: Beyond Discovery and Development

Cisplatin-DNA adduct repair of transcribed genes is controlled by two circadian programs in mouse tissues

Analysis of nanoparticle delivery to tumours

Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements

Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers

Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence

Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair

Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme